Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial

被引：0
|
作者：
Niels H. Brandt-Jacobsen
Marie Louise Johansen
Jon J. Rasmussen
Morten Dalsgaard
Thomas Kumler
Jens Faber
Patrick Rossignol
Morten Schou
Caroline Kistorp
机构：
[1] Copenhagen University Hospital - Rigshospitalet,Department of Endocrinology
[2] University of Copenhagen,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[3] Copenhagen University Hospital - Herlev and Gentofte Hospital,Department of Endocrinology
[4] Copenhagen University Hospital - Herlev and Gentofte Hospital,Internal Medicine
[5] Université de Lorraine,Department of Cardiology
[6] L’Institut National de la Santé et de la Recherche Médicale (URM-S 116),Department de Défaillance Cardiovasculaire Aiguë et Chronique
[7] Centre Hospitalier Régional Universitaire,Centre d’Investigation Clinique Plurithématique 1433
[8] French Clinical Research Infrastructure Network Investigation Network Initiative - Cardiovascular and Renal Clinical Trialists,undefined
[9] L’Institut National de la Santé et de la Recherche Médicale,undefined
来源：
BMC Cardiovascular Disorders | / 23卷
关键词：
Mineralocorticoid receptor antagonist; High-dose eplerenone; Global longitudinal strain; Systolic and diastolic function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial
    H. Brandt-Jacobsen, Niels
    Johansen, Marie Louise
    Rasmussen, Jon J.
    Dalsgaard, Morten
    Kumler, Thomas
    Faber, Jens
    Rossignol, Patrick
    Schou, Morten
    Kistorp, Caroline
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [2] Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
    Brandt-Jacobsen, Niels H.
    Johansen, Marie Louise
    Rasmussen, Jon
    Forman, Julie L.
    Holm, Maria Refsgaard
    Faber, Jens
    Rossignol, Patrick
    Schou, Morten
    Kistorp, Caroline
    DIABETES & METABOLISM, 2021, 47 (04)
  • [3] Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes Data From the MIRAD Trial
    Brandt-Jacobsen, Niels H.
    Madsen, Per Lav
    Johansen, Marie Louise
    Rasmussen, Jon J.
    Forman, Julie L.
    Holm, Maria R.
    Jorgensen, Niklas Rye
    Faber, Jens
    Rossignol, Patrick
    Schou, Morten
    Kistorp, Caroline
    JACC-HEART FAILURE, 2021, 9 (08) : 550 - 558
  • [4] Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial)
    Johansen, Marie L.
    Schou, Morten
    Rossignol, Patrick
    Holm, Maria R.
    Rasmussen, Jon
    Brandt, Niels
    Frandsen, Mikkel
    Chabanova, Elizaveta
    Dela, Flemming
    Faber, Jens
    Kistorp, Caroline
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2305 - 2314
  • [5] Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes A Randomized Clinical Trial
    Vanderheiden, Anna
    Harrison, Lindsay
    Warshauer, Jeremy
    Li, Xilong
    Adams-Huet, Beverley
    Lingvay, Ildiko
    JAMA INTERNAL MEDICINE, 2016, 176 (07) : 939 - 947
  • [6] Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes
    Matsumura, Takeshi
    Makabe, Tomoko
    Ueda, Seiko
    Fujimoto, Yuki
    Sadahiro, Kayo
    Tsuruyama, Shiori
    Ookubo, Yuma
    Kondo, Tatsuya
    Araki, Eiichi
    DIABETES THERAPY, 2022, 13 (09) : 1621 - 1634
  • [7] Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes
    Takeshi Matsumura
    Tomoko Makabe
    Seiko Ueda
    Yuki Fujimoto
    Kayo Sadahiro
    Shiori Tsuruyama
    Yuma Ookubo
    Tatsuya Kondo
    Eiichi Araki
    Diabetes Therapy, 2022, 13 : 1621 - 1634
  • [8] Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial
    Ersboll, Mads
    Jurgens, Mikkel
    Hasbak, Philip
    Kjaer, Andreas
    Wolsk, Emil
    Zerahn, Bo
    Brandt-Jacobsen, Niels H.
    Gaede, Peter
    Rossing, Peter
    Faber, Jens
    Inzucchi, Silvio E.
    Gustafsson, Finn
    Schou, Morten
    Kistorp, Caroline
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2022, 38 (03): : 579 - 587
  • [9] Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial
    Mads Ersbøll
    Mikkel Jürgens
    Philip Hasbak
    Andreas Kjær
    Emil Wolsk
    Bo Zerahn
    Niels H. Brandt-Jacobsen
    Peter Gæde
    Peter Rossing
    Jens Faber
    Silvio E. Inzucchi
    Finn Gustafsson
    Morten Schou
    Caroline Kistorp
    The International Journal of Cardiovascular Imaging, 2022, 38 : 579 - 587
  • [10] Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
    Bizino, Maurice B.
    Jazet, Ingrid M.
    Westenberg, Jos J. M.
    van Eyk, Huub J.
    Paiman, Elisabeth H. M.
    Smit, Jan W. A.
    Lamb, Hildebrandus J.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18
12345